McKesson Corporation $MCK Shares Acquired by PNC Financial Services Group Inc.

PNC Financial Services Group Inc. boosted its position in shares of McKesson Corporation (NYSE:MCK) by 24.3% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 242,256 shares of the company’s stock after purchasing an additional 47,352 shares during the period. PNC Financial Services Group Inc. owned approximately 0.19% of McKesson worth $187,152,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in MCK. IAM Advisory LLC grew its stake in McKesson by 0.3% during the 3rd quarter. IAM Advisory LLC now owns 3,908 shares of the company’s stock valued at $3,019,000 after purchasing an additional 13 shares in the last quarter. PDS Planning Inc grew its position in shares of McKesson by 1.1% during the third quarter. PDS Planning Inc now owns 1,209 shares of the company’s stock worth $934,000 after buying an additional 13 shares in the last quarter. Berkshire Asset Management LLC PA raised its holdings in McKesson by 4.6% in the third quarter. Berkshire Asset Management LLC PA now owns 294 shares of the company’s stock valued at $227,000 after acquiring an additional 13 shares in the last quarter. Cardinal Point Capital Management ULC boosted its stake in McKesson by 2.2% during the 2nd quarter. Cardinal Point Capital Management ULC now owns 645 shares of the company’s stock valued at $473,000 after acquiring an additional 14 shares during the last quarter. Finally, Goldstein Advisors LLC grew its holdings in McKesson by 4.4% during the 3rd quarter. Goldstein Advisors LLC now owns 334 shares of the company’s stock worth $258,000 after acquiring an additional 14 shares in the last quarter. Institutional investors and hedge funds own 85.07% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on MCK. Mizuho boosted their price target on McKesson from $880.00 to $885.00 and gave the company a “neutral” rating in a report on Thursday, February 5th. JPMorgan Chase & Co. boosted their target price on shares of McKesson from $983.00 to $1,107.00 and gave the company an “overweight” rating in a research note on Tuesday, February 10th. TD Cowen raised their price target on shares of McKesson from $1,000.00 to $1,012.00 and gave the stock a “buy” rating in a research report on Thursday, February 5th. Weiss Ratings downgraded shares of McKesson from a “buy (a-)” rating to a “buy (b+)” rating in a research report on Thursday, February 5th. Finally, Wells Fargo & Company raised their target price on shares of McKesson from $914.00 to $925.00 and gave the stock an “equal weight” rating in a report on Thursday, February 5th. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $937.07.

McKesson Trading Up 1.9%

Shares of NYSE MCK opened at $933.75 on Monday. McKesson Corporation has a twelve month low of $585.22 and a twelve month high of $971.93. The firm has a 50-day moving average of $840.13 and a two-hundred day moving average of $788.58. The company has a market capitalization of $114.38 billion, a price-to-earnings ratio of 26.86, a PEG ratio of 1.50 and a beta of 0.40.

McKesson (NYSE:MCK) last released its earnings results on Wednesday, February 4th. The company reported $9.34 EPS for the quarter, beating the consensus estimate of $9.19 by $0.15. The business had revenue of $106.16 billion during the quarter, compared to analyst estimates of $105.98 billion. McKesson had a net margin of 1.09% and a negative return on equity of 338.97%. The business’s quarterly revenue was up 11.4% on a year-over-year basis. During the same period in the prior year, the business earned $8.03 earnings per share. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. As a group, research analysts predict that McKesson Corporation will post 32.77 earnings per share for the current year.

McKesson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 1st. Investors of record on Monday, March 2nd will be paid a $0.82 dividend. The ex-dividend date of this dividend is Monday, March 2nd. This represents a $3.28 dividend on an annualized basis and a yield of 0.4%. McKesson’s dividend payout ratio (DPR) is currently 9.43%.

Insider Activity

In related news, CAO Napoleon B. Rutledge, Jr. sold 328 shares of the firm’s stock in a transaction that occurred on Friday, February 6th. The shares were sold at an average price of $955.00, for a total value of $313,240.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Thomas L. Rodgers sold 276 shares of the business’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $816.18, for a total transaction of $225,265.68. Following the sale, the executive vice president directly owned 2,268 shares in the company, valued at approximately $1,851,096.24. This trade represents a 10.85% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.08% of the stock is currently owned by insiders.

McKesson Profile

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.